Abstract:This epidemiologic assessment of population-based cohorts investigates the change in treatment for chronic kidney disease associated with population-based screening compared with measuring blood pressure and assessing glycemia. Question How frequently is population-based screening for chronic kidney disease (CKD) associated with a change in recommended treatment compared with a strategy of measuring blood pressure and assessing glycemia? Findings This epidemiologic assessment of 126 242 adults screened for CKD in population-based cohorts from China, India, Mexico, Senegal, and the United States found that most treatment gaps identified by population-based screening for CKD were apparent by measuring blood pressure or glycemic control. Case finding, defined by testing for CKD only in adults with hypertension or diabetes, was associated with a lower frequency of testing and a greater proportion of individuals with identified treatment gaps compared with screening. Meaning These findings suggest that case finding was more efficient than population-based screening and detected most patients with CKD requiring treatment changes. Importance Population-based screening for chronic kidney disease (CKD) is sometimes recommended based on the assumption that detecting CKD is associated with beneficial changes in treatment. However, the treatment of CKD is often similar to the treatment of hypertension or diabetes, which commonly coexist with CKD. Objective To determine the frequency with which population-based screening for CKD is associated with a change in recommended treatment compared with a strategy of measuring blood pressure and assessing glycemia. Design, Setting, and Participants This cohort study was conducted using data obtained from studies that evaluated CKD in population-based samples from China (2007-2010), India (2010-2014), Mexico (2007-2008), Senegal (2012), and the United States (2009-2014), including a total of 126 242 adults screened for CKD. Data were analyzed from January 2020 to March 2021. Main Outcomes and Measures The primary definition of CKD was estimated glomerular filtration rate less than 60 mL/min/1.73 m(2). For individuals with CKD, the need for a treatment change was defined as not taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker or having blood pressure levels of 140/90 mm Hg or greater. For individuals with CKD who also had diabetes, the need for a treatment change was also defined as having hemoglobin A(1c) levels of 8% or greater or fasting glucose levels of 178.4 mg/dL (9.9 mmol/L) or greater. Case finding was defined as testing for CKD only in adults with hypertension or diabetes. Results Among 126 242 adults screened for CKD, there were 47 204 patients in the China cohort, 9817 patients in the India cohort, 51 137 patients in the Mexico cohort, 2441 patients in the Senegal cohort, and 15 643 patients in the US cohort. The mean age of participants was 49.6 years (95% CI, 49.5-49.7 years) in the China cohort, 42.9 years (95% CI, 42.6-43.2 years) in the India cohort, 51.6 years (95% CI, 51.5-51.7 years) in the Mexico cohort, 48.2 years (95% CI, 47.5-48.9 years) in the Senegal cohort, and 47.3 years (95% CI, 46.6-48.0 years) in the US cohort. The proportion of women was 57.3% (95% CI, 56.9%-57.7%) in the China cohort, 53.4% (95% CI, 52.4%-54.4%) in the India cohort, 68.8% (95% CI, 68.4%-69.2%) in the Mexico cohort, 56.0% (95% CI, 54.0%-58.0%) in the Senegal cohort, and 51.9% (51.0%-52.7%) in the US cohort. The prevalence of CKD was 2.5% (95% CI, 2.4%-2.7%) in the China cohort, 2.3% (95% CI, 2.0%-2.6%) in the India cohort, 10.6% (95% CI, 10.3%-10.9%) in the Mexico cohort, 13.1% (95% CI, 11.7%-14.4%) in the Senegal cohort, and 6.8% (95% CI, 6.2%-7.5%) in the US cohort. Screening for CKD was associated with the identification of additional adults whose treatment would change (beyond those identified by measuring blood pressure and glycemia) per 1000 adults: China: 8 adults (95% CI, 8-9 adults); India: 5 adults (95% CI, 4-7 adults); Mexico: 26 adults (95% CI, 24-27 adults); Senegal: 59 adults (95% CI, 50-69 adults); and the US: 19 adults (95% CI, 16-23 adults). Case finding was associated with the identification of 46.2% (95% CI, 45.1%-47.4%) to 86.4% (95% CI, 85.4%-87.3%) of individuals with CKD depending on the country, an increase in the proportion of individuals requiring a treatment change by as much 89.6% (95% CI, 80.4%-99.3%) in the US, and a decrease in the proportion of individuals needing GFR measurements by as much as 57.8% (95% CI, 56.3%-59.3%) in the US. Conclusions and Relevance This study found that most additional individuals with CKD identified by population-based screening programs did not need a change in treatment compared with a strategy of measuring blood pressure and assessing glycemia and that case finding was more efficient than screening for early detection of CKD.

Screening of Chronic Kidney Disease in Communities:confusion and challenges

[Chronic kidney disease in community: Current state for screening and management]

Community-based Screening for Chronic Kidney Disease among Populations Older Than 40 Years in Beijing.

Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines

Prevalence, Awareness, Treatment, and Control of Hypertension in the Non-Dialysis Chronic Kidney Disease Patients

Prevalence, awareness and treatment of chronic kidney disease among middle-aged and elderly: The China Health and Retirement Longitudinal Study.

Chronic kidney disease awareness, screening and prevention: Rationale for the design of a public education program

Screening for chronic kidney disease: change of perspective and novel developments

Asian Chronic Kidney Disease Best Practice Recommendations: Positional Statements for Early Detection of Chronic Kidney Disease from Asian Forum for Chronic Kidney Disease Initiatives (AFCKDI).

Community nephrology: audit of screening for renal insufficiency in a high risk population

Screening of Chronic Kidney Disease in Adults: A 10 years' Experience in North Indian City on World Kidney Day

Prevalence, awareness and treatment of chronic kidney disease among middle‐aged and elderly: The <scp>C</scp>hina <scp>H</scp>ealth and <scp>R</scp>etirement <scp>L</scp>ongitudinal <scp>S</scp>tudy

Exploring patient delay in people with chronic kidney disease: A cross-sectional study

Chronic Kidney Disease Screening Methods and Its Implication for Malaysia: An in Depth Review

Diagnostic Status of Chronic Kidney Disease in China – Results from 976,409 Individuals with Electronic Health Records

Diagnostic Yield of Population-Based Screening for Chronic Kidney Disease in Low-Income, Middle-Income, and High-Income Countries

Prevalence of chronic kidney disease and its association with metabolic diseases: a cross-sectional survey in Zhejiang province, Eastern China

Using eGFR and Albumin Creatinine Ratio as an Initial Screening Tool in Trinidadian Primary Care to Identify High-risk Population for CKD: A Cross-Sectional Study

Influence of Doctors’ Perception on the Diagnostic Status of Chronic Kidney Disease: Results from 976 409 Individuals with Electronic Health Records in China

What every clinician needs to know about chronic kidney disease: Detection, classification and epidemiology

Probability of chronic kidney disease and associated risk factors in Chinese adults: a cross-sectional study of 9 million Chinese adults in the Meinian One Health Screening Survey